NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $49.61 -1.95 (-3.78%) As of 11:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Travere Therapeutics Stock (NASDAQ:TVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$49.20▼$51.5450-Day Range$48.87▼$67.5152-Week Range$22.59▼$68.73Volume155,024 shsAverage Volume2.02 million shsMarket Capitalization$4.76 billionP/E RatioN/ADividend YieldN/APrice Target$72.55Consensus RatingModerate Buy Company Overview Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria. Travere is also advancing investigational therapies for rare conditions, including kidney diseases. Based in San Diego, California, Travere primarily serves patients and healthcare providers in the United States while pursuing the development of treatments for rare diseases more broadly. Eric Dube serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreTVTX MarketRank™: 3.61438679245 of 5 starsTravere Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 181st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialTravere Therapeutics has a consensus price target of $72.55, representing about 46.7% upside from its current price of $49.44.Amount of Analyst CoverageTravere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($0.90) to $3.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -38.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -38.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 206.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.42% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 4.74.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 12.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.35 News SentimentTravere Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Travere Therapeutics this week, compared to 5 articles on an average week.Search Interest4 people have searched for TVTX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,454,261.00 in company stock.Percentage Held by Insiders4.44% of the stock of Travere Therapeutics is held by insiders.Percentage Held by InstitutionsTravere Therapeutics has minimal institutional ownership at this time.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS) and Travere Therapeutics (TVTX)November 11 at 12:26 AM | theglobeandmail.comTravere Therapeutics (TVTX) Stock Price Target 2026November 7, 2026 | benzinga.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 13 at 1:00 AM | USA Capital Gold (Ad)What is HC Wainwright's Forecast for TVTX FY2026 Earnings?November 7, 2026 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Target Cut by GuggenheimNovember 6, 2026 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Stock Gets Price Target Increase from Canaccord Genuity GroupNovember 6, 2026 | americanbankingnews.comTravere Therapeutics, Inc. (TVTX) - What Are Investment Firms Saying About This Stock?November 5, 2026 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 243,735 Shares of StockOctober 20, 2026 | insidertrades.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $38.21 at the beginning of 2026. Since then, TVTX stock has increased by 29.4% and is now trading at $49.4420. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) posted its earnings results on Monday, November, 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.49. The company's revenue for the quarter was up 36.2% on a year-over-year basis. Read the conference call transcript. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' top institutional investors include Stephens Investment Management Group LLC (1.96%), Assenagon Asset Management S.A. (1.22%), Russell Investments Group Ltd. (0.81%) and Aberdeen Group plc (0.76%). Insiders that own company stock include Eric M Dube, Peter Heerma, Elizabeth E Reed, Jula Inrig, William E Rote, Jeffrey A Meckler, Christopher R Cline, Gary A Lyons, Timothy Coughlin, Sandra Calvin and Roy D Baynes. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Bloom Energy (BE), CrowdStrike (CRWD), Rigetti Computing (RGTI) and Tesla (TSLA). Company Calendar Last Earnings11/02/2026Today11/13/2026UBS Global Biopharma Conference 202611/16/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TVTX's financial health is in the Green zone, according to TradeSmith. TVTX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVTX CIK1438533 Webwww.travere.com Phone(888) 969-7879Fax302-645-1280Employees497Year Founded2011Price Target and Rating Average Price Target for Travere Therapeutics$72.55 High Price Target$86.00 Low Price Target$49.00 Potential Upside/Downside+46.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E Ratio16.37 P/E GrowthN/ANet Income-$25.55 million Net Margins-18.66% Pretax Margin-24.53% Return on Equity-185.69% Return on Assets-17.24% Debt Debt-to-Equity Ratio26.72 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$490.73 million Price / Sales9.67 Cash Flow$0.34 per share Price / Cash Flow143.70 Book Value$0.24 per share Price / Book206.01Miscellaneous Outstanding Shares95,990,000Free Float91,730,000Market Cap$4.75 billion OptionableOptionable Beta1.11 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:TVTX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts